December 08, 2023
The FII PRIORITY Asia Summit is taking place in Hong Kong. Dr. Liping Liu, Founder and CEO of HighTide Therapeutics, Inc. (“HighTide”) was invited to present at the summit on the topic of "How to Upgrade the Human-tech Interface?”. HighTide was invited to attend the Future Investment Initiative Institute (FII Institute) international summit for the second consecutive time this year. The FII PRIORITY Asia Summit is designed to explore the key megatrend priorities through inspiring dialogue. It aims to translate aspirations into tangible actions, effecting meaningful change on a global scale with international CEOs, business leaders, policy makers, world-renowned entrepreneurs, academics, experts, and other distinguished guests.
The FII PRIORITY Asia Summit is conducted in partnership between the Government of the Hong Kong Special Administrative Region of the People's Republic of China (HKSAR), Hong Kong Exchanges and Clearing Limited (HKEX) and FII Institute. The FII Institute is the most important and largest international economic and investment organization in the Middle East, and its flagship event, the FII Conference, is known as "Davos in the Desert". FII Institute, proposed by Saudi Crown Prince Mohammed, is chaired by Yasir Al-Rumayyan, President of the Governor of the Public Investment Fund (PIF). It is managed by Princess Reema Bint Bandar Al Saud, Saudi Ambassador to the United States of America; Sen. Matteo Renzi, Senator of the Italian Republic, Former Prime Minister of Italy, several civic leaders, entrepreneurial pioneers, and noted academics. FII PRIORITY is a groundbreaking summit that brings together visionaries from business, government, civil society, and technology (THINK) to seamlessly translate aspirations into actionable initiatives (ACT) and facilitate transformative change (XCHANGE).
The theme of the FII PRIORITY Asia Summit in Hong Kong is "Megatrends Shaping Humanity." This theme seeks to foster innovation and sustainable development by leveraging the potential of emerging trends to enhance human life. It aspires to broaden global perspectives and unite efforts for the advancement of human society. Over 1,000 of the world's leading investors and business leaders in the field of healthtech, AI, circular economy, food security and greentech will attend the summit, including Yasir Al-Rumayyan, President of the Governor of the Public Investment Fund and Chairman of FII Institute; and Laura Cha, Chairman of HKEX.
Dr. Liping Liu, Founder and CEO of HighTide joins Lady Irene Hong, Founding Partner of CEC Capital Group, Lady Ivanna Putri Dato Salehudin, Founder and CEO of Samoedra Pty Ltd and Lady Edie Lush, world-renowned host in the session titled "How to Upgrade the Human-tech Interface?” to discuss the current state of healthcare, longevity, AI and biotech, and explore strategies for ensuring their affordability and accessibility. Dr. Liu has showcased to the world the therapeutic potential of HTD1801, an original multi-functional, multi-targeted drug, in enhancing overall human health.
Having attended two consecutive FII Institute International Summits in person this year, Dr. Liu expressed her profound sentiments about her participation in FII PRIORITY: "FII PRIORITY is not just a summit; it stands as a powerful call to action that transcends boundaries, uniting experts from across the globe. It is delightful to be in the company of distinguished individuals from diverse backgrounds at the Asia Summit. Through this event, we showcased to the world the therapeutic potential of HTD1801 in the realm of chronic disease management. As one of the 20 representative strategic enterprises to be acknowledged by the HK Government, HighTide is committed to leveraging its extensive expertise and strengths. We will conduct thorough investigations into the utilization of natural products, aiming to develop innovative therapeutic solutions for age-related diseases, so as to drive technological breakthroughs and contribute to the global advancement of fields related to anti-aging and the treatment of chronic illnesses."
About HighTide Therapeutics
HighTide Therapeutics, Inc. is a globally integrated biopharmaceutical company focusing on the discovery and development of first-in-class multifunctional multi-targeted therapies with poly-indications across metabolic and digestive diseases with significant unmet medical needs. The company is developing multiple clinical assets, including therapy for nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2DM), severe hypertriglyceridemia (SHTG), primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC). Berberine ursodeoxycholate (HTD1801), the company’s lead drug candidate, received Fast Track designation from the U.S. FDA for both NASH and PSC, as well as Orphan Drug designation for PSC. In China, HTD1801 has been included in the National Major New Drug Innovation Program under the 13th Five-Year Plan for Major Technology Project.
The information contained herein is based solely on events or data available as of the date of this document. Unless required by law, we are under no obligation to update or publicly revise any forward-looking statements or events beyond those anticipated, even if new information, future events, or other circumstances arise after the date of the forward-looking statement. Please review this document carefully and be aware that our actual future performance or results may significantly deviate from expectations. All statements in this document are made as of the publication date and may change considering future developments.
For more information, please visit www.hightidetx.com.